These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38968122)

  • 1. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Zaidi S; Park J; Chan JM; Roudier MP; Zhao JL; Gopalan A; Wadosky KM; Patel RA; Sayar E; Karthaus WR; Kates DH; Chaudhary O; Xu T; Masilionis I; Mazutis L; Chaligné R; Obradovic A; Linkov I; Barlas A; Jungbluth AA; Rekhtman N; Silber J; Manova-Todorova K; Watson PA; True LD; Morrissey C; Scher HI; Rathkopf DE; Morris MJ; Goodrich DW; Choi J; Nelson PS; Haffner MC; Sawyers CL
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2322203121. PubMed ID: 38968122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.
    Zaidi S; Park J; Chan JM; Roudier MP; Zhao JL; Gopalan A; Wadosky KM; Patel RA; Sayar E; Karthaus WR; Henry Kates D; Chaudhary O; Xu T; Masilionis I; Mazutis L; Chaligné R; Obradovic A; Linkov I; Barlas A; Jungbluth A; Rekhtman N; Silber J; Manova-Todorova K; Watson PA; True LD; Morrissey CM; Scher HI; Rathkopf D; Morris MJ; Goodrich DW; Choi J; Nelson PS; Haffner MC; Sawyers CL
    bioRxiv; 2024 Apr; ():. PubMed ID: 38645034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
    Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
    Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
    Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
    Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 9. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
    Venkadakrishnan VB; Presser AG; Singh R; Booker MA; Traphagen NA; Weng K; Voss NCE; Mahadevan NR; Mizuno K; Puca L; Idahor O; Ku SY; Bakht MK; Borah AA; Herbert ZT; Tolstorukov MY; Barbie DA; Rickman DS; Brown M; Beltran H
    Nat Commun; 2024 Aug; 15(1):6779. PubMed ID: 39117665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
    Yin J; Daryanani A; Lu F; Ku AT; Bright JR; Alilin ANS; Bowman J; Lake R; Li C; Truong TM; Twohig JD; Mostaghel EA; Ishikawa M; Simpson M; Trostel SY; Corey E; Sowalsky AG; Kelly K
    Prostate; 2024 Aug; 84(11):1033-1046. PubMed ID: 38708958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDHu40: a novel marker gene set of neuroendocrine prostate cancer.
    Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
    Brief Bioinform; 2024 Sep; 25(6):. PubMed ID: 39318189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular events in neuroendocrine prostate cancer development.
    Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
    Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
    Bhattacharya S; Harris HL; Islam R; Bodas S; Polavaram N; Mishra J; Das D; Seshacharyulu P; Kalluchi A; Pal A; Kohli M; Lele SM; Muders M; Batra SK; Ghosh PM; Datta K; Rowley MJ; Dutta S
    Cell Death Dis; 2024 Aug; 15(8):617. PubMed ID: 39183332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.